Open company research · DHR
Danaher
Bioprocessing equipment and consumables through Cytiva
Sources checked 2026-10-21 · Source review; evidence limits noted belowResearch question
Validated biological purification workflows and consumable continuity
What limits delivery, and how quickly can qualified alternatives expand?
Reported evidence
Danaher identifies Cytiva, including the Pall Life Sciences business, within its biotechnology portfolio.
- Danaher: Cytiva biotechnology business ↗Source: date not provided · Checked 2026-10-21
- Cytiva: chromatography resins for biomanufacturing ↗Source: date not provided · Checked 2026-10-21
- Danaher: Q3 2026 results ↗Source: 2026-10-21 · Checked 2026-10-21
Our interpretation
Bioprocess tools support drug manufacturing; the AI-biotech theme does not establish separately disclosed AI revenue.
Capacity and delivery
- The cited product documentation does not quantify current customer-accepted annual output. Source ↗
What to monitor
- Biotechnology demand versus customer inventory replenishment
- Process validation, recurring consumables and capacity utilization
What would weaken the case?
- Customers destock or add competing validated suppliers
- Process intensification reduces consumable spend per batch
Reported financial exposure
- Sales
- 6,554 USD millionQ3 2026 · GAAP · Source ↗
- Operating profit
- 1,245 USD millionQ3 2026 · GAAP · Source ↗
Constraint-specific revenue, pricing power and valuation are not quantified. Product relevance does not establish pure-play exposure.
Valuation and the share of revenue attributable to this specific constraint are not quantified here. GAAP, adjusted and segment measures retain their source definitions.Continue in the Atlas →